HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Massachusetts Prop 65 clone legislation

This article was originally published in The Rose Sheet

Executive Summary

In a March 10 letter, CTFA opposes enactment of H 2251, which would require warnings on products containing "toxic substances that threaten the environment or can cause cancer, birth defects and other serious health effects." The group argues that the measure is unnecessary because consumer products "are already subject to a comprehensive array of state and federal laws and regulations that assure their safety and mandate appropriate warnings." The bill, introduced by Rep. John McDonough (D-Boston) Nov. 3, also was opposed by the Nonprescription Drug Manufacturers Association and the Grocery Manufacturers of America at a March 8 hearing before the House Natural Resources and Agriculture Committee. Massachusetts Public Interest Research Group testified in support of the bill. Legislation similar to H 2251 died in Massachusetts in 1991 and 1992

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel